分析PD-1/PD-L1抗体在肿瘤免疫治疗中的应用进展

Application of PD-1 and PD-L1 Antibodies in Tumor Immunotherapy

近年来,免疫治疗被广泛应用于肿瘤治疗中。该治疗方式是肿瘤治疗领域重要的突破,在血液肿瘤治疗中T细胞(嵌合抗原受体)发挥着重要的作用,在黑素瘤治疗中T细胞受体(抗原特异性)基因对T淋巴细胞进行转导,其潜能巨大。美国食品和药品管理局在2011年对T淋巴细胞蛋白4(细胞毒性)予以批准。PD-1/PD-L1应用到肿瘤免疫治疗中近年来越来越受到临床的关注。在肿瘤治疗中应用PD-1抑制剂,尤其在晚期肺鳞状细胞癌中应用,相比多西他赛,优势更为明显,可延长患者的生存期。本文主要对肿瘤免疫治疗中PD-1/PD-L1抗体的应用进展进行综述。

In recent years,tumor therapy has been widely used in immunotherapy,which is an important breakthrough point,in the treatment of blood tumor by t cells(chimeric antigen receptor),the T cell receptor(antigen specific)gene transduction of T cell lymphocyte in melanoma therapy has great potential in the application of antibodies to CTLA4 by the FDA in 2011,T lymphocyte 4(cytotoxicity)approved.The use of PD-1,PD-L1 in tumor immunotherapy has received increasing attention in recent years.The use of PD-1 inhibitors in tumor therapy,especially in advanced lung squamous-cell carcinoma,is more advantageous than docetaxel,it prolongs the patient's life.In this review,we focus on the progress of the application of PD-1,PD-L1 antibody in tumor immunotherapy.